# A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma

> **NCT04322292** · PHASE1 · COMPLETED · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 9 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** C-CAR088

## Key facts

- **NCT ID:** NCT04322292
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-12
- **Primary completion:** 2022-09-22
- **Final completion:** 2022-09-22
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2026-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04322292

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04322292, "A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04322292. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*